FLT3 Inhibitors in AML

被引：0
|
作者：
Stone, R. M. [1 ]
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, Adult Leukemia Program, Boston, MA 02115 USA
来源：
ANNALS OF HEMATOLOGY | 2015年 / 94卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：101 / 102
页数：2
相关论文
共 50 条
  • [31] Chemical Space of FLT3 Inhibitors as Potential Anti-AML Drugs
    Lan, Qing-Yuan
    Zhi, Yan-Le
    Heng, Hao
    Tian, Jie-Yi
    Guo, Xiao-Xing
    Liu, Hai-Chun
    Chen, Ya-Dong
    Lu, Tao
    Lu, Shuai
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2017, 12 (04) : 296 - 322
  • [32] Rational discovery of dual FLT3/HDAC inhibitors as a potential AML therapy
    Wang, Zhijie
    Wu, Donglin
    Zhao, Xiaofei
    Liu, Canlin
    Jia, Siming
    He, Qindi
    Huang, Fei
    Cheng, Zitian
    Lu, Tao
    Chen, Yadong
    Chen, Yun
    Yang, Pei
    Lu, Shuai
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 260
  • [33] FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
    Pratz, Keith W.
    Sato, Takashi
    Murphy, Kathleen M.
    Stine, Adam
    Rajkhowa, Trivikram
    Levis, Mark
    BLOOD, 2010, 115 (07) : 1425 - 1432
  • [34] Targeting NADPH oxidases improves response to FLT3 inhibitors for the treatment of AML
    Germon, Zac
    Sillar, Jonathan
    Mannan, Abdul
    Duchatel, Ryan
    Murray, Heather
    Douglas, Alicia
    Huang, Honggang
    Alvaro, Frank
    Chamberlain, Janis
    Wei, Andrew
    De Luliis, Geoffry
    Enjeti, Anoop
    Larsen, Martin
    Verrills, Nicole
    Dun, Matthew
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 59 - 59
  • [35] Incorporating a FLT3 inhibitor into AML therapy
    Levis, M. J.
    Small, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Inhibition of FLT3 in AML: a focus on sorafenib
    Antar, A.
    Otrock, Z. K.
    El-Cheikh, J.
    Kharfan-Dabaja, M. A.
    Battipaglia, G.
    Mahfouz, R.
    Mohty, M.
    Bazarbachi, A.
    BONE MARROW TRANSPLANTATION, 2017, 52 (03) : 344 - 351
  • [37] Inhibition of FLT3 in AML: a focus on sorafenib
    A Antar
    Z K Otrock
    J El-Cheikh
    M A Kharfan-Dabaja
    G Battipaglia
    R Mahfouz
    M Mohty
    A Bazarbachi
    Bone Marrow Transplantation, 2017, 52 : 344 - 351
  • [38] The growing landscape of FLT3 inhibition in AML
    Smith, Catherine C.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2019, : 539 - 547
  • [39] Targeted Therapy of FLT3 mutated AML
    Fiedler, W.
    Heuser, M.
    Kayser, S.
    Kebenko, M.
    Krauter, J.
    Salih, H. R.
    Goetze, K.
    Stamm, H.
    Latuske, E.
    Wellbrock, J.
    Doehner, K.
    Ganser, A.
    Doehner, H.
    Schlenk, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 21 - 21
  • [40] FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
    Sato, Takashi
    Yang, Xiaochuan
    Knapper, Steven
    White, Paul
    Smith, B. Douglas
    Galkin, Steven
    Small, Donald
    Burnett, Alan
    Levis, Mark
    BLOOD, 2011, 117 (12) : 3286 - 3293
12345